目的探討重組人生長激素(rhGH)在體外對人直腸癌細胞增殖的影響。方法實驗分為對照組、rhGH組、奧沙利鉑(LOHP)組和rhGH+LOHP組4組,利用體外細胞培養(yǎng)、MTT比色技術及流式細胞儀等方法,測定不同濃度的rhGH對人直腸癌細胞株HR8348細胞倍增時間、細胞抑制率、細胞周期、增殖指數(shù)(PI)和DNA抑制率的影響。結果rhGH在體外不促進HR8348細胞的分裂增殖,rhGH組與對照組比較,以及rhGH+LOHP組與LOHP組比較,其差異均無統(tǒng)計學意義(P gt;0.05); rhGH+LOHP組與對照組比較及rhGH+LOHP組與對應的rhGH組配對比較,細胞倍增時間明顯延長,細胞抑制率增加,阻滯于G0~G1期的細胞數(shù)增加,S期和G2~M期細胞明顯減少,PI明顯降低,DNA抑制率顯著升高(P<0.01,S期P<0.05)。結論rhGH在體外不促進直腸癌細胞的分裂增殖。
引用本文: 陳嘉勇,甘平,梁道明,譚晶,張毅. 重組人生長激素在體外對人直腸癌細胞株HR8348增殖的影響. 中國普外基礎與臨床雜志, 2003, 10(4): 362-365. doi: 復制
版權信息: ?四川大學華西醫(yī)院華西期刊社《中國普外基礎與臨床雜志》版權所有,未經授權不得轉載、改編
1. | 祁小平,黎介壽,陳徹. 人生長激素對癌細胞株周期動力學的影響 [J]. 腸內與腸外營養(yǎng), 2000; 7(2)∶83. |
2. | Estrov Z, Meir R, Barak Y, et al. Human growth hormone and insulinlike growth factor1 enhance the proliferation of human leukemic blasts [J]. J Clin Oncol, 1991; 9(3)∶394. |
3. | Raff T, Germann G. Growth hormone in surgeryan assessment of current knowledge [J]. Chirurg, 1997; 68(10)∶995. |
4. | 陳嘉勇,張捷,譚晶,等. 胃、 結腸癌患者術后生長激素應用的價值評估 [J]. 中國普外基礎與臨床雜志, 1999; 6(6)∶365. |
5. | OgilvyStuart AL, Shalet SM. Tumour occurrence and recurrence [J]. Horm Res, 1992; 38(Suppl 1)∶50. |
6. | Jauch KW, Heiss MM, Gruetzner U, et al. Prognostic significance of bone marrow micrometastases in patients with gastric cancer [J]. J Clin Oncol, 1996; 14(6)∶1810. |
7. | Heiss MM, Allgayer H, Gruetzner KU, et al. Individual development and uPAreceptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer [J]. Nat Med, 1995; 1(10)∶1035. |
8. | Fiebig HH, Dengler W, Hendriks HR. No evidence of tumor growth stimulation in human tumors in vitro following treatment with recombinant human growth hormone [J]. Anticancer Drugs, 2000; 11(8)∶659. |
9. | Bartlett DL, Stein TP, Torosian MH, et al. Effect of growth hormone and protein intake on tumor growth and host cachexia [J]. Surgery, 1995; 117(3)∶260. |
10. | Torosian MH,Donoway RB. Growth hormone inhibits tumors metastasis [J]. Cancer, 1991; 67(9)∶2280. |
11. | Wennbo H, GebreMedhin M, GritliLinde A, et al. Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice [J]. J Clin Invest, 1997; 100(11)∶2744. |
- 1. 祁小平,黎介壽,陳徹. 人生長激素對癌細胞株周期動力學的影響 [J]. 腸內與腸外營養(yǎng), 2000; 7(2)∶83.
- 2. Estrov Z, Meir R, Barak Y, et al. Human growth hormone and insulinlike growth factor1 enhance the proliferation of human leukemic blasts [J]. J Clin Oncol, 1991; 9(3)∶394.
- 3. Raff T, Germann G. Growth hormone in surgeryan assessment of current knowledge [J]. Chirurg, 1997; 68(10)∶995.
- 4. 陳嘉勇,張捷,譚晶,等. 胃、 結腸癌患者術后生長激素應用的價值評估 [J]. 中國普外基礎與臨床雜志, 1999; 6(6)∶365.
- 5. OgilvyStuart AL, Shalet SM. Tumour occurrence and recurrence [J]. Horm Res, 1992; 38(Suppl 1)∶50.
- 6. Jauch KW, Heiss MM, Gruetzner U, et al. Prognostic significance of bone marrow micrometastases in patients with gastric cancer [J]. J Clin Oncol, 1996; 14(6)∶1810.
- 7. Heiss MM, Allgayer H, Gruetzner KU, et al. Individual development and uPAreceptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer [J]. Nat Med, 1995; 1(10)∶1035.
- 8. Fiebig HH, Dengler W, Hendriks HR. No evidence of tumor growth stimulation in human tumors in vitro following treatment with recombinant human growth hormone [J]. Anticancer Drugs, 2000; 11(8)∶659.
- 9. Bartlett DL, Stein TP, Torosian MH, et al. Effect of growth hormone and protein intake on tumor growth and host cachexia [J]. Surgery, 1995; 117(3)∶260.
- 10. Torosian MH,Donoway RB. Growth hormone inhibits tumors metastasis [J]. Cancer, 1991; 67(9)∶2280.
- 11. Wennbo H, GebreMedhin M, GritliLinde A, et al. Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice [J]. J Clin Invest, 1997; 100(11)∶2744.